Etoposide

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHhUHNRUUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> NVvZNlhNOjV7NkCyPFI>
KellyCis83 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PyWWlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= MkTkNlU6PjB{OEK=
SK-N-AS NWXUdlA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjtdolKSzVyPUCuNlTjiIoEsfMAjVAvODNizszN NFjFXmozPTl4MEK4Ni=>
SK-N-ASCis24 M4H6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTiZ2JpUUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> NGXTd48zPTl4MEK4Ni=>
U87 M1;KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHMNE02OCEQvF2= NXnwOHNwPDhiaB?= MUTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? NXzseVhUOjV5NUCyO|M>
HCT116 NI\XbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrNeoMxNjVvMj61JO69VQ>? M13sXFQ5yqCqwrC= NHP5d3BKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NX3SZ21qOjV5NE[3OlM>
HT-29 M1rvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLJNE42NTJwNTFOwG0> NVnIcnVsPDkEoHlCpC=> NGPQbZdKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= MWOyOVc1Pjd4Mx?=
Caco2 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHTWGYxNjVvMj61JO69VQ>? MXm0POKhcMLi MnzKTWM2OD15LkK2xsDDucLiMT62POKh|ryP NHTacHYzPTd2Nke2Ny=>
COLO 205 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfZNE42NTJwNTFOwG0> M{HFblQ5yqCqwrC= M3H4V2lEPTB;MT62NeKhyrIEoECuNFLDqM7:TR?= NVPSV|FbOjV5NE[3OlM>
SW480 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nlfFAvPS1{LkWg{txO MlXNOFjDqGkEoB?= MoCwTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP NY[3TWQ4OjV5NE[3OlM>
HEK293T NGnmT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq2NU02KM7:TR?= M2DrVFQ5yqCqwrC= MUPJR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? NIDKTYYzPTd2Nke2Ny=>
Hep3B  NYrsW2J3TnWwY4Tpc44hSXO|YYm= NVvNSGRIOTBizszN MV[0POKhcMLi MWry[YR2[2W|IITo[UBmdmijbnPpcoch\W[oZXP0JI9nKEKPUD22 M{DyOlI2PjN|NU[0
Hep3B  MlP4SpVv[3Srb36gRZN{[Xl? MUiwMlEuOTBizszN MXiyOEBp MlnLd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D M1y2TlI2PjN|NU[0
HEK293 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzlOmw6UUN3ME23MlE1yqEEsdMgNE4{PsLizszN MXKyOVYxOzF{Mh?=
DU145 NIrWTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0UJlKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= MkjoNlU3ODNzMkK=
HCT15 NWD4d4lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP2Z3hKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= MUOyOVYxOzF{Mh?=
T47D MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? NGPKcJEzPTZyM{GyNi=>
SMMC-7721 NGXZ[FFHfW6ldHnvckBCe3OjeR?= NHe1bWE1OCEQvF2= NVXUS45pPDhiaB?= NGDlTmdFVVOR MofBbY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> MUiyOVU1PDN4MR?=
MDA-MB-231 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr6O|LDqGh? MoXNTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? NIjhXZMzPTR6NkKxPS=>
MCF-7 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLKO|LDqGh? NIXtVFdKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= NVT3dXV4OjV2OE[yNVk>
Jurkat M1r6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NuKhcA>? Mn3mTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? NGmwfnYzPTR6NkKxPS=>
HeLa NIHlRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX4Zo84PzMEoHi= NH;EOFNKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP MkLWNlU1QDZ{MUm=
MCF7  NUTCcG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXy1MVExOCEQvF2= NWLBRZk5PyCm NU\COoZTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVSyOVQ4OjZzOR?=
K562 NUT1ZnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG3NuKhcA>? MmjlTWM2OD1yLkK5xsDPxE1? MXuyOVI5OjZ3Mx?=
K/VP.5 NFjZTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfoO|LDqGh? MmG0TWM2OD12LkpCpO69VQ>? M{Lu[|I2Ojh{NkWz
SH-EP  NEH5dphHfW6ldHnvckBCe3OjeR?= M{P3TFIxyqEQvHevcYw> NHnnbHkzPMLiaB?= M4Pu[olv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= MnXzNlUzPjF7OEG=
SCC25 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[yOOKhcA>? MlrjTWM2OD12Mz6zxsDDucLiMT6xNuKh|ryP MV6yOVIzODd{OR?=
CAL27 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWeyOOKhcA>? MXXJR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? MVyyOVIzODd{OR?=
FaDu M2qxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPublczPMLiaB?= MYTJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP MXOyOVIzODd{OR?=
SCC25 NF3YS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojLOFjDqGh? NYXGT2FZUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> NV\MTmtjOjV{MkC3Nlk>
CAL27 NWnYOllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG2bmp2PDkEoHi= M4HWeWlEPTB;MUiuNlTDqMLzwrCxMlE2yqEQvF2= M3i2bVI2OjJyN{K5
FaDu NGHweYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXEcW04PDkEoHi= Mn\HTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP M3jqZ|I2OjJyN{K5
SCC25 NF7nPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnDO|LDqGh? M{js[mlEPTB;OD60NeKhyrIEoEGuNVHDqM7:TR?= MVuyOVIzODd{OR?=
CAL27 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe3NuKhcA>? NITXV3BKSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= NYD3PINHOjV{MkC3Nlk>
FaDu M1yyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HoSlczyqCq NH7RR2ZKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= M1jtUlI2OjJyN{K5
MCF-7 M{XzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PPOlQ5yqCqwrC= MoW5SG1UVw>? MlLnTWM2OD15LkNCpOKyyqByLklCpO69VQ>? MVqyOVIyPjN5OB?=
T-47D NEnk[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS0POKhcMLi M3TtU2ROW09? MWPJR|UxRTdwN9MgxtHDqDBwN9Mg{txO M{XhNFI2OjF4M{e4
MDA-MB-231 M1;IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHOOFjDqGkEoB?= MnPCSG1UVw>? M1;GXmlEPTB;MUKuPOKhyrIEoEGuNOKh|ryP MX6yOVIyPjN5OB?=
DU145 NWDEVHpSSXCxcITvd4l{KEG|c3H5 NVXYUG5yOTBvMUCwJO69VQ>? NEfxSWY5KGh? NUPTZ|BUTE2VTx?= M1q3[Ilv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NUTLPXpIOjVzNEm2PFE>
DU145 stem-like MlH0RZBweHSxc3nzJGF{e2G7 M3e2OFExNTFyMDFOwG0> NYDuRoJYQCCq MWjEUXNQ M2qyd4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVXjeGM{OjVzNEm2PFE>
DU145 MX;GeY5kfGmxbjDBd5NigQ>? MYmxNE0yODBizszN NYLP[5QyOiCq M3:zdmROW09? NWLvZnR1cW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3jRS|I2OTR7Nkix
DU145 stem-like NE\5O4lHfW6ldHnvckBCe3OjeR?= NFq2PYQyOC1zMECg{txO MX2yJIg> NIrGOopFVVOR MUXpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIjIRoEzPTF2OU[4NS=>
UW228-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M360eVAvODFvM{CwJO69VQ>? MoK1OFghcA>? NVziNmp7TE2VTx?= NYXwfJF3UUN3ME2wMlk6yqEQvF2= NFW1fIwzPTFzOUG4OS=>
NSCs NInZe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HX[lAvODFvM{CwJO69VQ>? NVPnUIxOPDhiaB?= MUnEUXNQ MXnJR|UxRTBwMz2zxsDPxE1? NFjZPHUzPTFzOUG4OS=>
MKL-1  MXLGeY5kfGmxbjDBd5NigQ>? MonKNVAuOTByMDDuUS=> MY[0JIQ> NXT2cIZScW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= M4LXeFI2OTF4N{W0
MCF7 EV NG\tcnNHfW6ldHnvckBCe3OjeR?= MkfPNVAuOTByIN88US=> NF7wWYwz6oDLaB?= NYDQNGRncW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? M4DQOFI2ODh6MkCz
MCF 7BMI1 NVv4b3FKTnWwY4Tpc44hSXO|YYm= NHXaN4cyOC1zMECg{txO Mm\WNwKBkWh? NGLvcVFqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NVTuV295OjVyOEiyNFM>
MCF7 EV NHm5WHBHfW6ldHnvckBCe3OjeR?= NUH1c4Z6OTBvMUCwJO69VQ>? MYOy5qCKcA>? NWG0b5N1TVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MnzrNlUxQDh{MEO=
MCF7 BMI1 MXfGeY5kfGmxbjDBd5NigQ>? NGnO[owyOC1zMECg{txO NYq4SHNxOuLCiXi= MYrFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= M3\VZ|I2ODh6MkCz
HepG2 NEH3fFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXGbGVFVVORwrC= M2SwcWlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= NHv5epAzPTB5OEOxNS=>
MOLT-3 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HPNWROW00EoB?= MWDJR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= MofrNlUxPzh|MUG=
HT1080 NY\qR2pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[ydVEuOTByIN88US=> NX;SXpNkPC9{ND:0PEBp NIHHeYVFVVORwrC= MVLpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NWrQbnpzOjVyN{iwOlQ>
HT1080 NYGx[m1NTnWwY4Tpc44hSXO|YYm= MnTpNE4xODBzLUGwNEDPxE1? NWi1bmNiOS1{NDDo NV7CRnZPTE2VT9Mg MmfmbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MkLXNlUxPzhyNkS=
HT1080 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXnSlFIOC5yMECxMVExOCEQvF2= M4TXc|I1KGh? NFO5XplFVVORwrC= NYDIdpd5[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> NEnoeFAzPTB5OEC2OC=>
HD-MY-Z NFzrfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPpNlQwPDhxN{KgbC=> MoP2TWM2OO,:nkGwNEDPxE1? M4LTdlI2ODR6MkO2
DOHH-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUiyOEBp M3rQZWlEPTExvK6xNFAh|ryP NIHLUoQzPTB2OEKzOi=>
DOHH-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:0PEBp M1e4XWlEPTB;MUmuPeKh|ryP MoP5NlUxPDh{M{[=
DOHH-2 NHH0W2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPxfHpMPzJiaB?= MkDkTWM2OD13wrFOwG0> NWHNc2VHOjVyNEiyN|Y>
REH MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLXbm4zPCCq MX3JR|UxRTBwMEK3xsDPxE1? M4LYSlI2ODR6MkO2
REH M4TseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHIOFghcA>? MkPiTWM2OD1yLkCxOOKh|ryP NYTOO3hMOjVyNEiyN|Y>
REH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS3NkBp MnLkTWM2OD1yLkCxOeKh|ryP NGDZU3EzPTB2OEKzOi=>
HH NFrnO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYiyOEBp Mm\aTWM2OD1zMESuO:Kh|ryP Mm[yNlUxPDh{M{[=
HH NWHHOZVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nub|Q5KGh? M2n2WmlEPTB;NEiuOuKh|ryP MWCyOVA1QDJ|Nh?=
HH M{DIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3flc|czKGh? NGSwd5pKSzVyPUG0MlfDqM7:TR?= NVnVeI81OjVyNEiyN|Y>
HuT-78 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfGNlQhcA>? NHjYSXBKSzVyPUmuN:Kh|ryP MkS5NlUxPDh{M{[=
HuT-78 NUfZU4dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDwU3Y1QCCq MnnVTWM2OD12LkRCpO69VQ>? Mmn6NlUxPDh{M{[=
HuT-78 NXOwdYdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn1O|IhcA>? M3LTe2lEPTB;ND6yxsDPxE1? MXiyOVA1QDJ|Nh?=
OPM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCwNlQhcA>? NGLHVI5KSzVyPUK0MlHDqM7:TR?= Ml;XNlUxPDh{M{[=
OPM-2 NYDzWHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfSOXVyPDhiaB?= NITmPYlKSzVyPUVCpO69VQ>? NGfvNpUzPTB2OEKzOi=>
OPM-2 NYq3d5hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XCPVczKGh? NFf3eppKSzVyPUGuN:Kh|ryP Mn74NlUxPDh{M{[=
RPMI-8226 NXTSco84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTMV5U4OjRiaB?= MX;JR|UxRTFyNj62xsDPxE1? MlrLNlUxPDh{M{[=
RPMI-8226 M4Lafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K4Z|Q5KGh? NUTYSIRQUUN3ME25NU4yyqEQvF2= MkniNlUxPDh{M{[=
RPMI-8226 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3joRVczKGh? M4PIZ2lEPTB;MUSuPeKh|ryP MnzoNlUxPDh{M{[=
U-266 NWjydHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULYTJdrOjRiaB?= MU\JR|UxRTh4LkNCpO69VQ>? MYqyOVA1QDJ|Nh?=
U-266 NUDRcFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfjbGR4PDhiaB?= NXLuSFFRUUN3ME22PE41yqEQvF2= M1izUlI2ODR6MkO2
U-266 NWLNZYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPUTnBMPzJiaB?= MlrQTWM2OD1{Nz60xsDPxE1? NVXIPY1pOjVyNEiyN|Y>
Kelly NETLOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUewMVExKM7:TR?= NXqxNYxXPzMEoHi= M2fWSmlEPTB;MT61NVjDqM7:TR?= MnzoNlUxODh7MEC=
SH-SY5Y  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrSWlRYOC1zMDFOwG0> NG[2dpQ4OsLiaB?= NIC3cpZKSzVyPUCuO|U1yqEQvF5CpC=> M4\VbVI2ODB6OUCw
SK-N-AS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKwMVExKM7:TR?= M3rvSFczyqCq M4TXSWlEPTB;MT63NVLDqM7:TdMg NFuzV5IzPTByOEmwNC=>
SK-N-DZ NVLad|M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr5NE0yOCEQvF2= MVu3NuKhcA>? MnvGTWM2OD13LkS4OeKh|ryP MonvNlUxODh7MEC=
HepG2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXiO2Q1QMLiaB?= MnPVSG1UV8Li M{fJO2lEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= M4LteVI1QTl4MUO2
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXVSW1SPDkEoHi= MVnEUXNQyqB? NGq5e3dKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> M{ewOlI1QTl4MUO2
MCF7 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Lyc|Q5yqCq NU\XS5pFTE2VT9Mg NH\TNZpKSzVyPUixMlA6yqEEsdMgNVQvOjIEoN88US=> M{jodVI1QTl4MUO2
HL-60  NIrDfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fQ[FczyqCq MmPQTWM2OD1yLkGy5qCG|ryP Mme1NlQ6QTNyMUS=
HL-60[R] MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXMO|LDqGh? M1vESWlEPTB;Mz6xNwKBjc7:TR?= MoHsNlQ6QTNyMUS=
MIAPACA MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvHTVUxRTFwMzFCtUAxNjB|IN88US=> NU[zUnd7OjR7NUO4NlE>
MCF-7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzW[I5IUTVyPUCuNlUhyrFiMD6xJO69VQ>? MWqyOFk2Ozh{MR?=
HeLa NHniZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITjR3VIUTVyPUCuOlQhyrFiMD60JO69VQ>? NGr2fpczPDl3M{iyNS=>
MO59K  NVH4cZo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm3JIQ> NX65SZVKUUN3ME2wMlE46oDHzszN NEW4W4YzPDl3M{W2NS=>
MO59J Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\H[|ch\A>? MoDGTWM2OD1yLkJihKXPxE1? NFnySXkzPDl3M{W2NS=>
ME 180 NGLl[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPnTpZWPDkEoHlCpC=> NX;aW2Q4UUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= NG\nV3QzPDl3M{CyOy=>
MCF-7 M4XwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfHcnZLPDkEoHlCpC=> NEnm[IlKSzVyPUKzMlkhyrFiMD6z5qCG|ryP M3HHOFI1QTV|MEK3
HeLa MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG0POKhcMLi NGfaZVBKSzVyPUSuO|EhyrFiMT605qCG|ryP NHH3eFAzPDl3M{CyOy=>
MDA-MB-453 M1PBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrjVWNPPDkEoHlCpC=> MX7JR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? NVfFPFR5OjR7NUOwNlc>
MDA-MB-231 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[0POKhcMLi MYXJR|UxRTJ2LkKyJOKyKDJwOUVihKXPxE1? NXPtWGgzOjR7NUOwNlc>
PC-3 NH;mNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\SdpI1QMLiaNMg MlT5TWM2OD1zND60JOKyKDNwMkRihKXPxE1? NH72PJUzPDl3M{CyOy=>
HT-29 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfLV|A1QMLiaNMg M3O3NGlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= NU\nZVE4OjR7NUOwNlc>
BGC-823 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrvcphKPDkEoHlCpC=> Mlm4TWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP MXiyOFc6Ozh5Nx?=
HeLa M{XofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;jT25FPDkEoHlCpC=> NG\qUY9KSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> M3jnUFI1Pzl|OEe3
A549 NFTxb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\sWJB1PDkEoHlCpC=> NFrEb2hKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN NYrjNGVEOjR5OUO4O|c>
HK-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TrcFQ5yqCqwrC= NX7NOpF[UUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= M3XVPFI1Pzl|OEe3

... Click to View More Cell Line Experimental Data

体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
+ 展开

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
+ 展开
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
稳定性 powder
in solvent
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03583424 Recruiting Hematopoietic Cell Transplantation Recipient|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) July 9 2018 Phase 1|Phase 2
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT03519971 Recruiting Non-Small Cell Lung Cancer AstraZeneca April 9 2018 Phase 3
NCT03407144 Recruiting Hodgkin Lymphoma Merck Sharp & Dohme Corp. April 9 2018 Phase 2
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT03432598 Recruiting Locally Advanced or Metastatic Lung Cancer BeiGene August 9 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID